Xentria Entered into an Exclusive Multi-Year License Agreement with Meitheal to Commercialize XTMAB-16 for Pulmonary Sarcoidosis in North America
Shots:
- Xentria will receive $45M up front, ~$35M upon regulatory submission and approval of XTMAB-16, and ~$600M in potential milestone-based royalties. Xentria will transfer the XTMAB-16 intellectual property to Meitheal’s parent company, King Friend Industry if the royalties pass $600M
- Meitheal to get an exclusive right to commercialize XTMAB-16 in North America while Xentria remains responsible for clinical development and holds the marketing rights in all other countries
- Additionally, preclinical data for XTMAB-16 demonstrated an ability to reduce the activation of an inflammatory pathway implicated in pulmonary sarcoidosis
Ref: Businesswire | Image: aTyr Pharma
Related News:- aTyr Pharma Reports the First Patient Dosing in the P-III (EFZO-FIT) Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
